Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ$31.17
Market Cap
$1.74B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
862 of 924
Rank in Industry
52 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SUPN Insider Trading Activity
SUPN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $15,579,913 | 16 | 100 |
Related Transactions
| Rubin Jonathan | SVP, Chief Medical Officer | 0 | $0 | 1 | $36,292 | $-36,292 |
| Hudson Frederick M. | director | 0 | $0 | 1 | $316,434 | $-316,434 |
| NEWHALL CHARLES W III | director | 0 | $0 | 1 | $387,768 | $-387,768 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT | 0 | $0 | 1 | $554,700 | $-554,700 |
| GEMAYEL GEORGES | director | 0 | $0 | 3 | $1.23M | $-1.23M |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | 0 | $0 | 7 | $3.94M | $-3.94M |
| Khattar Jack A. | President, CEO | 0 | $0 | 2 | $9.12M | $-9.12M |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The …
Insider Activity of Supernus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $15.58M worth of Supernus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $6.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,400 shares for transaction amount of $379,964 was made by Khattar Jack A. (President, CEO) on 2019‑08‑23.
List of Insider Buy and Sell Transactions, Supernus Pharmaceuticals, Inc.
| 2025-02-21 | Sale | Rubin Jonathan | SVP, Chief Medical Officer | 927 0.0019% | $39.15 | $36,292 | -6.24% | |
| 2025-02-04 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 9,477 0.0182% | $39.70 | $376,237 | -17.93% | |
| 2025-01-28 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 700 0.0013% | $39.62 | $27,734 | -12.82% | |
| 2024-12-03 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 12,745 0.0229% | $36.68 | $467,487 | -0.30% | |
| 2024-11-11 | Sale | NEWHALL CHARLES W III | director | 10,700 0.019% | $36.24 | $387,768 | +0.51% | |
| 2024-11-08 | Sale | Khattar Jack A. | President, CEO | 125,000 0.2259% | $36.29 | $4.54M | +0.38% | |
| 2024-11-08 | Sale | Hudson Frederick M. | director | 8,722 0.0158% | $36.28 | $316,434 | +0.38% | |
| 2024-11-08 | Sale | GEMAYEL GEORGES | director | 10,787 0.0195% | $36.30 | $391,568 | +0.38% | |
| 2024-11-07 | Sale | Khattar Jack A. | President, CEO | 125,000 0.2286% | $36.68 | $4.58M | +0.85% | |
| 2024-11-07 | Sale | GEMAYEL GEORGES | director | 14,213 0.026% | $36.62 | $520,480 | +0.85% | |
| 2024-11-07 | Sale | Mottola Frank | SVP, Quality, GMP, Ops, IT | 15,000 0.0277% | $36.98 | $554,700 | +0.85% | |
| 2024-09-13 | Sale | GEMAYEL GEORGES | director | 10,000 0.0183% | $31.33 | $313,300 | +14.98% | |
| 2024-03-21 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 14,491 0.0266% | $35.31 | $511,677 | -7.34% | |
| 2024-03-20 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 400 0.0007% | $35.31 | $14,124 | -6.31% | |
| 2024-03-19 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 12,364 0.0227% | $35.31 | $436,573 | -6.93% | |
| 2024-03-13 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 62,366 0.1107% | $33.74 | $2.1M | -5.28% | |
| 2024-03-12 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 3,884 0.0071% | $32.99 | $128,133 | -0.11% | |
| 2024-02-26 | Sale | Bhatt Padmanabh P. | Sr. VP of IP, CSO | 5,000 0.0094% | $30.21 | $151,050 | +11.59% | |
| 2024-01-10 | Sale | Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 8,000 0.0146% | $27.91 | $223,280 | +10.70% | |
| 2023-11-16 | Sale | NEWHALL CHARLES W III | director | 2,500 0.0046% | $28.01 | $70,025 | +6.96% |
Total: 145
*Gray background shows transactions not older than one year
Insider Historical Profitability
21.96%
| Khattar Jack A. | President, CEO | 926172 1.6594% | $28.87M | 3 | 20 | +14.22% |
| NEWHALL CHARLES W III | director | 130275 0.2334% | $4.06M | 1 | 2 | +29.48% |
| Hudson Frederick M. | director | 28395 0.0509% | $885,072.15 | 1 | 3 | +29.48% |
| NEW ENTERPRISE ASSOCIATES 11 LP | 10 percent owner | 10641250 19.0654% | $331.69M | 1 | 0 | +29.48% |
| Abingworth Management LTD | 10 percent owner | 3600000 6.4499% | $112.21M | 1 | 0 | +29.48% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$910,099,463 | 123 | 11.52% | $2.54B | |
$12,681,496 | 70 | 20.90% | $810.72M | |
$14,599,168 | 59 | 12.79% | $1.34B | |
$23,522,750 | 59 | -6.74% | $5.1B | |
$86,177,559 | 48 | 44.65% | $13.97B |
SUPN Institutional Investors: Active Positions
| Increased Positions | 145 | +51.06% | 3M | +4.73% |
| Decreased Positions | 116 | -40.85% | 3M | -5.15% |
| New Positions | 42 | New | 835,444 | New |
| Sold Out Positions | 22 | Sold Out | 248,236 | Sold Out |
| Total Postitions | 313 | +10.21% | 60M | -0.41% |
SUPN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $320,534.00 | 17.85% | 10M | -68,996 | -0.69% | 2024-12-31 |
| Vanguard Group Inc | $197,193.00 | 10.98% | 6.15M | +22,852 | +0.37% | 2024-12-31 |
| Armistice Capital, Llc | $155,042.00 | 8.64% | 4.84M | -260,000 | -5.1% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $92,286.00 | 5.14% | 2.88M | -3,960 | -0.14% | 2024-12-31 |
| Macquarie Group Ltd | $84,283.00 | 4.69% | 2.63M | -2,990 | -0.11% | 2024-12-31 |
| State Street Corp | $70,154.00 | 3.91% | 2.19M | +31,779 | +1.47% | 2024-12-31 |
| Stephens Investment Management Group Llc | $56,171.00 | 3.13% | 1.75M | -180,141 | -9.32% | 2024-12-31 |
| Polar Capital Holdings Plc | $54,115.00 | 3.01% | 1.69M | -250,000 | -12.9% | 2024-12-31 |
| Renaissance Technologies Llc | $51,255.00 | 2.86% | 1.6M | -129,900 | -7.51% | 2024-12-31 |
| Pacer Advisors, Inc. | $51,214.00 | 2.85% | 1.6M | -155,426 | -8.87% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.